Here’s how analysts see Merck & Co., Inc. (NYSE:MRK) after this past week.

April 26, 2018 - By Kurt Siggers

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment decreased to 0.94 in 2017 Q4. Its down 0.12, from 1.06 in 2017Q3. It turned negative, as 94 investors sold Merck & Co., Inc. shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported.
Somerset Gru Llc stated it has 0.17% in Merck & Co., Inc. (NYSE:MRK). Segall Bryant & Hamill Lc, Illinois-based fund reported 116,949 shares. Horizon Kinetics Ltd Liability Corp holds 47,550 shares or 0.08% of its portfolio. 716,547 were accumulated by Haverford Trust Com. Srb Corporation reported 1.88 million shares. Regent Invest Management Limited Liability holds 0.78% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 42,495 shares. Martin Currie Limited stated it has 229,924 shares or 0.91% of all its holdings. Guggenheim Capital Limited Co, a Illinois-based fund reported 1.54M shares. Jolley Asset Mngmt Limited Liability Corp invested 1.91% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Edgemoor Inv Advsrs Incorporated reported 124,736 shares. Moreover, Birmingham Co Al has 1.57% invested in Merck & Co., Inc. (NYSE:MRK) for 72,769 shares. Mai Cap invested in 0.23% or 70,861 shares. Security Tru has invested 0.52% in Merck & Co., Inc. (NYSE:MRK). Utah Retirement stated it has 0.6% in Merck & Co., Inc. (NYSE:MRK). Banced Corp has 0.48% invested in Merck & Co., Inc. (NYSE:MRK).

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 17 analysts covering Merck \u0026 Co (NYSE:MRK), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Merck \u0026 Co had 32 analyst reports since October 30, 2017 according to SRatingsIntel. The company was maintained on Monday, February 26 by Jefferies. The firm earned “Buy” rating on Monday, October 30 by UBS. Bank of America maintained Merck & Co., Inc. (NYSE:MRK) rating on Tuesday, April 17. Bank of America has “Buy” rating and $70 target. On Friday, November 3 the stock rating was maintained by Cowen & Co with “Hold”. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Citigroup on Monday, October 30. As per Monday, October 30, the company rating was downgraded by Barclays Capital. The company was maintained on Tuesday, January 16 by Jefferies. SunTrust downgraded the stock to “Hold” rating in Monday, October 30 report. Jefferies maintained the shares of MRK in report on Friday, April 13 with “Hold” rating. The rating was maintained by Morgan Stanley on Wednesday, February 7 with “Equal-Weight”. Below is a list of Merck & Co., Inc. (NYSE:MRK) latest ratings and price target changes.

23/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $73.0000 Upgrade
20/04/2018 Broker: Cowen & Co Rating: Hold New Target: $67.0000 Maintain
17/04/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $68 New Target: $70 Maintain
17/04/2018 Broker: Guggenheim Rating: Buy New Target: $72.0000 Maintain
17/04/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Old Target: $63 Upgrade
13/04/2018 Broker: Jefferies Rating: Hold New Target: $56.0000 Maintain
05/04/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Overweight Upgrade
23/03/2018 Broker: Jefferies Rating: Hold New Target: $55.0000 Maintain
12/03/2018 Broker: Leerink Swann Rating: Buy New Target: $66.0 Upgrade
26/02/2018 Broker: Jefferies Rating: Hold New Target: $56.0 Maintain

The stock decreased 0.05% or $0.03 during the last trading session, reaching $59.6. About 8.12 million shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since April 26, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $160.49 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 68.51 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: